Dexcom Q3 Earnings Beat Street, Raises FY21 Outlook Ahead Of G7 Launch


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Dexcom Inc's (NASDAQ:DXCMQ3 adjusted EPS of $0.89 though lower than $0.94 posted a year ago, came in sharply above the consensus of $0.63.
  • Sales increased 30% Y/Y to $650.20 million, surpassing the consensus of $617.82 million.
  • Volume growth and strong new customer additions continue to be the primary driver of revenue growth as awareness of real-time Continuous Glucose Monitoring (CGM) increases.
  • The Company achieved an adjusted gross margin of 68.7% versus 68% a year ago.
  • Adjusted operating income increased from $95 million to $123.8 million.
  • Dexcom ended Q3 with $2.70 billion in cash, cash equivalents, and marketable securities.
  • "We are pleased to once again be in a position to raise our full-year revenue and margin guidance as we drive toward a strong conclusion of 2021 and the upcoming launch of our Dexcom G7 system," said Kevin Sayer, Chairman, President & CEO.
  • Guidance: Dexcom forecasts revenue of $2.425 billion - 2.450 billion (consensus of $2.4 billion) compared to prior guidance of $2.35 billion - $2.4 billion.
  • Price Action: DXCM shares traded higher by 2.40 at $584 on the last check Friday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs